Stoke Therapeutics Comes Out of Seed Mode With $40M and Ex-Sarepta CEO at Its Helm Post author:Sam Post published:January 3, 2018 Post category:BioPharma The Series A round was entirely funded by founding investor Apple Tree Partners. Source: BioSpace You Might Also Like Auris Abandons Hearing-Loss Drug After Phase III Flop, Stock Sinks November 27, 2017 SYGNIS Reports Financial Results For The Second Quarter And First Six Months Of 2017 August 2, 2017 This Bay Area Biotech Snags $293 Million Pain Drug Pact With Novartis AG May 7, 2017
